Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NALIRIFOX (Ipsen)
- Development stage
- Unknown
- Lead developer
- Ipsen
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
NALIRIFOX is a combination chemotherapy regimen consisting of liposomal irinotecan, oxaliplatin, 5-fluorouracil (5-FU), and leucovorin. It is primarily utilized as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC) and is under investigation for locally advanced pancreatic cancer (LAPC). The regimen exerts its therapeutic effect through multiple mechanisms: irinotecan (in a liposomal formulation) inhibits DNA topoisomerase I, oxaliplatin acts as a platinum-based DNA alkylating agent, and 5-fluorouracil is an antimetabolite that inhibits thymidylate synthase, with leucovorin serving to enhance its binding. In the pivotal Phase III NAPOLI-3 trial, NALIRIFOX demonstrated superior overall survival and progression-free survival compared to the gemcitabine plus nab-paclitaxel (GnP) regimen, leading to its FDA approval in early 2024.
- Other names
- liposomal irinotecan + oxaliplatin + fluorouracil + leucovorin
02
Targets
dsDNA (Double-stranded DNA)TOP1 (DNA Topoisomerase I)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on NALIRIFOX (Ipsen).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NALIRIFOX (Ipsen).